CDKN2A and cancer: For example, it has been shown in cancer cell lines that MTAP loss (present in >99% of tumors with CDKN2A loss) results in an accumulation of the metabolite 5′-methylthioadenosine (MTA) in tumor cells and the extracellular environment.